Brief: Orexo Develops A Nasal Adrenaline Medication

Orexo AB

02/12/2021 07:03

Dec 2 (Reuters) - Orexo AB  ORX.ST :
    * OREXO DEVELOPS A NASAL ADRENALINE MEDICATION BASED ON THE
NOVEL
AMORPHOX TM  PLATFORM
    * DEVELOPMENT PIPELINE IS BROADENING WITH A NASAL ADRENALINE
MEDICATION
    * DEVELOPMENT AND COMMERCIAL PARTNERSHIPS WILL BE CONSIDERED
    * WILL EXPLORE OPPORTUNITIES FOR DEVELOPMENT- AND
COMMERCIALIZATION PARTNERSHIPS DURING 2022
    * IS OPTIMIZING OX640 FORMULATION AND EXPECTS TO PERFORM 
FIRST
EXPLORATIVE HUMAN CLINICAL PHARMACOKINETIC STUDY IN H2 2022
    * WILL BE ABLE TO LEVERAGE INVESTMENTS AND LEARNINGS MADE
FROM
OX124 AND OX125 PROJECTS  IN CONTINUED DEVELOPMENT

Source text for Eikon:  ID:nWkr1JnZGz 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))